Literature DB >> 17031146

Treatment of Helicobacter pylori.

J S Hoffman1, D R Cave.   

Abstract

Helicobacter pylori causes several gastroduodenal diseases. Various antibiotic regimens are available that eradicate H. pylori in 80 to 90% of patients, but no regimen cures all patients. Dual therapy is now obsolete. Triple therapy with two antibiotics and either a proton pump inhibitor or bismuth is the regimens of choice. Metronidazole and clarithromycin are the two key antibiotics. Antibiotic resistance against these two drugs is becoming more problematic and should be taken into consideration when choosing a regimen. Antibiotic resistance is usually induced after failure. Quadruple therapy has been used as a salvage regimen in failed cases but it is also the most complicated regimen. Several new agents are being studied including a single capsule that contains bismuth, metronidazole, and tetracycline.

Entities:  

Year:  2001        PMID: 17031146     DOI: 10.1097/00001574-200101000-00006

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  15 in total

Review 1.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Two atypical L-cysteine-regulated NADPH-dependent oxidoreductases involved in redox maintenance, L-cystine and iron reduction, and metronidazole activation in the enteric protozoan Entamoeba histolytica.

Authors:  Ghulam Jeelani; Afzal Husain; Dan Sato; Vahab Ali; Makoto Suematsu; Tomoyoshi Soga; Tomoyoshi Nozaki
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

3.  Esomeprazole: a review of its use in the management of acid-related disorders in the US.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Helicobacter pylori culture and antimicrobial resistance in Iran.

Authors:  Gholam-Hossein Fallahi; Shohreh Maleknejad
Journal:  Indian J Pediatr       Date:  2007-02       Impact factor: 1.967

6.  Irigenin, a novel lead from Iris confusa for management of Helicobacter pylori infection with selective COX-2 and HpIMPDH inhibitory potential.

Authors:  Passent M Abdel-Baki; Moshera M El-Sherei; Amal E Khaleel; Marwa M Abdel-Aziz; Mona M Okba
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

7.  Oxalobacter formigenes and its potential role in human health.

Authors:  Sylvia H Duncan; Anthony J Richardson; Poonam Kaul; Ross P Holmes; Milton J Allison; Colin S Stewart
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

Review 8.  Esomeprazole: a review of its use in the management of acid-related disorders.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran.

Authors:  Leila Shokrzadeh; Fereshteh Jafari; Hossein Dabiri; Kaveh Baghaei; Homayoun Zojaji; Amir H Alizadeh; Mohammad Mehdi Aslani; Mohammad R Zali
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

10.  Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States.

Authors:  William M Duck; Jeremy Sobel; Janet M Pruckler; Qunsheng Song; David Swerdlow; Cindy Friedman; Alana Sulka; Balasubra Swaminathan; Tom Taylor; Mike Hoekstra; Patricia Griffin; Duane Smoot; Rick Peek; David C Metz; Peter B Bloom; Steven Goldschmidt; Julie Parsonnet; George Triadafilopoulos; Guillermo I Perez-Perez; Nimish Vakil; Peter Ernst; Steve Czinn; Donald Dunne; Ben D Gold
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.